Original filing text · Part I

Item 3 — Quantitative and Qualitative Disclosures About Market Risk

Nektar Therapeutics · 10-Q · Q2 FY2026 · Period ended Jun 30, 2026

This is the extracted source text from the SEC filing. Formatting may differ from the original document.

Our market risks at June 30, 2026 have not changed materially from those discussed in Item 7A of our Annual Report on Form 10-K for the year ended December 31, 2025 on file with the SEC.